PARP inhibitors and cancer therapy - early results and potential applications.
Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.
Jones
C
C
Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Plummer
E R
ER
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D000077204:Temozolomide
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D003606:Dacarbazine; D000077204:Temozolomide